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REGULATING THE DIETARY
SUPPLEMENTS INDUSTRY:
SOMETHING STILL NEEDS TO CHANGE
Debra D. Burke*and Anderson P. Page
I. INTRODUCTION

As Americans have become increasingly interested in diet and good
health, it is not surprising that the dietary supplement industry has enjoyed
a substantial level of sales and an impressive growth curve. Dietary
supplement products generated sales of nearly $13 billion in 19971 - up
from $10 billion in 1996.2 A recent report estimated that Americans spend
over $18 billion annually on over 29,000 supplements sold in the United
States.3 Consumers have embraced supplements, because of a perception
that such aids are safer and more natural than prescription drugs. 4 By
regulatory definition, a dietary supplement is a product taken by mouth that

* Professor of Business Law, Western Carolina University.

J.D., M.P.A., B.A.

University of Texas at Austin.
** B.S./B.A., Western Carolina University.
1. Cassandra Burke Robertson, Separating Snake Oil from Therapeutic Supplements.
The Nexus Between Litigation and Regulation in the Dietary Supplement Industry, 35 U.
TOL. L. REV. 317, 317 (2003).
2. CTR.
FOR
FOOD
SAFETY
AND APPLIED
NUTRITION,
FDA, ECONOMIC
CHARACTERIZATION OF THE DIETARY SUPPLEMENT INDUSTRY FINAL REPORT § 2.1.1 (March

1999),
at
http://vm.cfsan.fda.gov/-comm/ds-econ2.html
[hereinafter
ECONOMIC
CHARACTERIZATION FINAL REPORT].
3. Dietary Supplements: Nature's Answer to Cost Effective Preventative Medicine:
Hearing Before the Subcomm. on Human Rights and Wellness of the House Comm. on
Government Reform, 108th Cong. 1 (Sept. 22, 2004) (opening statement of Chairman Dan
Burton).
4. Robertson, supra note 1, at 318-19.
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contains a "dietary ingredient" intended to supplement a diet.5 The
"ingredient" may be vitamins, minerals, herbs, botanicals, amino acids, and
substances such as enzymes, organ and glandular tissues, concentrates,
constituents, extracts, and metabolites.6 Supplements can be formulated
into tablets, capsules, softgels, gelcaps, liquids, powders, or bars.7
The most widely used supplements include vitamins, minerals, herbs,
and botanicals. In all, nearly $5 billion worth of vitamins were sold in
1996, accounting for nearly half (48 percent) of all dietary supplement
sales.8 While thirteen substances have been identified as vitamins
necessary for humans, 9 one, Vitamin C, drives the industry with 60,000
tons produced annually. 10
Other widely used supplements include
minerals, defined as "[i]norganic substances that humans require in
quantities greater than 100 milligrams per day," and trace elements, which
are "[inorganic substances] required in quantities less than 100 milligrams
per day.''
Minerals are required for numerous biological
and
12
physiological processes necessary for the maintenance of health.
Botanicals are also classified by the U.S. Food and Drug
Administration (FDA) as a dietary ingredient. I3 Botanical supplements,
including teas, 14 are produced from fresh, dried, or otherwise preserved
plants or parts of plants.15 These botanicals are "becoming increasingly
valued by some consumers for their perceived medicinal properties;
however, FDA regulations prevent statements that these products are
intended to diagnose, treat, cure, or prevent disease., 16 Beyond actual

5.

CTR. FOR FOOD SAFETY AND APPLIED NUTRITION,

FDA,

OVERVIEW OF DIETARY

SUPPLEMENTS, at http://www.cfsan.fda.gov/-dms/ds-oview.html#what (last modified Jan. 4,
2002) [hereinafter OVERVIEW OF DIETARY SUPPLEMENTS].

6. Id.
7. Id.
8. ECONOMIC CHARACTERIZATION

FINAL REPORT, supra note 2, at § 5.1.1,

at

http://vm.cfsan.fda.gov/-comm/ds-econ5.html#1.
9. Id. at § 2.1.1, at http://vm.cfsan.fda.gov/-comm/ds-econ2.html#1.
10. Id. at § 2 tbl.2. 1, at http://vm.cfsan.fda.gov/~comm/ds-econ2.html#1.
11. Id. at § 2.1.2, at http://vm.cfsan.fda.gov/-comm/ds-econ2.html#1.
12. Id. at § 4.1.2, at http://vm.cfsan.fda.gov/-comm/ds-econ4.html#1.
13. OVERVIEW OF DIETARY SUPPLEMENTS, supra note 5.
14. ECONOMIC CHARACTERIZATION FINAL REPORT, supra note 2, at § 2.1.3,
http://vm.cfsan.fda.gov/-comm/ds-econ2.html#1.

15. Id.
16. Id. at § 4.1.3, at http://vm.cfsan.fda.gov/-comm/ds-econ4.html#1.

at
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supplements, consumers are spending their money on information; sales
of
17
books on botanicals and herbs amounted to $94 million in 1996 alone.
There are now 1,555 manufacturing facilities for dietary supplements,
with 268 distributors and 209 importers. 18 In 1997, the total sales for the
top fifteen companies were over $3 billion. 19 One company alone, Leiner
Health Products, a private-label supplement manufacturer, reported sales of
$425 million in 1994.20 Another company, Lederle (now Wyeth), had sales
of $67 million in 1994 from just one product, Centrum, the number-one
selling dietary supplement.21 In many cases, supplement manufacturers
and distributors are able to generate huge sales volumes, because of the
lack of government regulation of their products.22
As is true for the food industry, ensuring the safety of the goods ranks
highest with manufacturers of dietary supplements as well. 23 Since the
FDA can attempt to regulate dietary supplements only after they enter the
market, 24 consumers can be at risk, sometimes great risk, of injury from
using unsafe products. This article will examine the role of the FDA in
regulating the dietary supplement industry, as well as the role of the FTC in
regulating supplement advertising, taking into account First Amendment
concerns. It will conclude that reforms are needed to assure an informed
consumer choice with respect to safety issues. The article proposes that the
FDA assume a more proactive stance with respect to the substantiation of
safe use, including the evaluation of risks associated with the ingestion of
dietary supplements, while permitting the FTC to police misleading claims
regarding effectiveness claims by marketers of supplements.

17.

Id. at § 4.3.2, at http://vm.cfsan.fda.gov/-comm/ds-econ4.html#1.

18. Id. at § 3 tbl.3.1, at http://vm.cfsan.fda.gov/-comm/ds-econ3.html#1.
19. Id. at § 3 tbl.3.5, at http://vm.cfsan.fda.gov/-comm/ds-econ3.html#1.
20. Id.
21. Id. at § 5 tbl.5.2, at http://vm.cfsan.fda.gov/-comm/ds-econ5.html#1.
22. Consider, for example, that the FDA can remove a supplement from the
marketplace only after it is shown to pose a "significant or unreasonable" health risk.
Robertson, supra note 1, at 321. Also, consider that the Federal Trade Commission ("FTC")
can force a supplement advertisement off the air only after it finds the claims to be false or
misleading.
FTC, A BRIEF OVERVIEW OF THE FEDERAL TRADE COMMISSION'S
INVESTIGATIVE

AND

LAW

ENFORCEMENT

AUTHORITY,

at

http://www.ftc.gov/ogc/brfovrvw.htm (last modified Sept. 2002).
23. CTR. FOR FOOD SAFETY AND APPLIED NUTRITION, FDA, DIETARY SUPPLEMENT
HEALTH AND EDUCATION ACT OF 1994, at http://www.cfsan.fda.gov/-dms/dietsupp.html
(last modified Dec. 1, 1995).
24. OVERVIEW OF DIETARY SUPPLEMENTS, supra note 5.
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II. FEDERAL FOOD AND DRUG ADMINISTRATION REGULATION
A. BACKGROUND

The FDA, as it is known today, clearly illustrates the evolution of
government regulation. What began in the early 1900's as the Bureau of
Chemistry has become the government's primary tool in overseeing the
laws concerning most "food products, human and animal drugs, therapeutic
agents of biological origin, medical devices, radiation-emitting products,
cosmetics, and animal feed." 25 Early regulatory acts passed by Congress
include the Drug Importation Act of 1848, which banned the importation of
adulterated drugs, and the Biologics Act of 1902, which was designed to
ensure the purity and safety of serums and vaccines. 26 The Food and Drug
Act of 1906 banned adulterated or misbranded food or drugs from interstate
commerce, and made the manufacture of these products unlawful, 27 while
the Sherley Amendment to the Act28 passed in 1912 prohibited false and
fraudulent curative claims on labels.
The responsibilities of the FDA in this regulatory scheme have been
systematically expanded by, for example, the 1938 Federal Food, Drug,
25. Food products include dietary supplements, but exclude food and poultry.
FDA,
HISTORY
OF
THE
FDA,
http://www.fda.gov/oc/history/historyoffda/default.htm (last visited Mar. 16,
[hereinafter FDA HISTORY].
26. FDA,
MILESTONES

IN

U.S.

FOOD

AND

DRUG

LAW

P.
at
2005)

JOHN

SWANN,

HISTORY,

at

http://www.fda.gov/opacom/backgrounders/miles.html (last modified Aug. 5, 2002)
(providing a comprehensive chronological listing and description of pertinent legislation).
27. Pub. L. No. 59-384, 34 Stat. 768 (1906) (codified at 21 U.S.C. §§ 1-15 (1934))
(repealed in 1938). This legislation was passed in response to Upton Sinclair's novel The
Jungle, which chronicled filthy conditions in the Chicago meatpacking industry. Literature
Network,
Upton Sinclair
Biography and Works, at http://www.onlineliterature.com/upton sinclair (last visited Mar. 16, 2005).
28. Congress enacted the Sherley Amendment to overcome a Supreme Court ruling in a
case involving "Johnson's Mild Combination Treatment for Cancer" - a worthless product
that bore false therapeutic claims on its label. United States v. Johnson, 221 U.S. 488, 499
(1911). The Court held that unlike false and misleading claims regarding the identity of a
drug, claims regarding the curative or remedial effect of a product were not within the scope
of the Food and Drugs Act of June 30, 1906. Id. at 497-98. The Sherley Amendment
expressly "prohibits labeling medicines with false therapeutic claims intended to defraud the
purchaser," however, the FDA bears a difficult burden of proof in establishing that claims

were both false and fraudulent.
LINE:

CHRONOLOGY

OF

CTR. FOR DRUG EVALUATION AND RESEARCH,

DRUG

REGULATION

http://www.fda.gov/cder/about/history/timel.htm#1912

[hereinafter

DRUG REGULATION TIME LINE].

IN

THE

(last

UNITED

visited

Mar.

FDA,

TIME

at
2005)

STATES,

16,
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and Cosmetics Act (the "FDCA"), which added regulatory power and
functions to the Agency's scientific mission. 29 This Act was for
"preventing the manufacture, sale, or transportation of adulterated or
misbranded or poisonous or deleterious foods, drugs, medicine, and liquors,
and for regulating traffic therein, and for other purposes." 3° Although
providing evidence of safety before marketing was first required by the
FDCA, it was not until the Kefauver Drug Amendments of 1962 that firms
also had to show a drug's effectiveness before marketing. 31 These acts,
along with subsequent legislation, put substantial regulatory power in the
hands of the FDA.
B. FDA DRUG APPROVAL PROCESS
Under the FDCA, the FDA has the power to regulate drugs, food, and
cosmetics.
Located within the FDA are centers with specialized
responsibilities to insure that the risk posed by the product versus the
benefit to be gained through its use, is carefully evaluated. The Center for
Drug Evaluation and Research (the "CDER") is the one responsible for
assuring that drugs are safe and effective. 32 Created in 1987, it is the

29. FDA HISTORY, supra note 25. The 1938 Act was passed in response to the
Sulfanilamide elixir tragedy, in which many children died after taking the self-proclaimed
"wonder drug."
FDA, THE EVOLUTION OF U.S. DRUG LAW,
at
http://www.fda.gov/fdac/special/newdrug/benlaw.html
(last visited Mar. 16, 2005)
[hereinafter DRUG LAW EVOLUTION]. The amendments provided that no new drugs could be
marketed until they had been declared safe by the FDA, gave the FDA injunctive power,
regulated cosmetics for the first time, and gave the FDA the authority to set food standards.
DRUG REGULATION TIME LINE, supra note 28.
30. Pub. L. 75-717, 52 Stat. 1040 (1938). Further, the 1951 Durham-Humphrey
Amendment defined the kinds of drugs that cannot be used without medical supervision and
a prescription. Drug Law Evolution, supra note 29.
31. DIXIE FARLEY, BENEFIT Vs. RISK: HoW FDA APPROVES NEW DRUGS, FDA
CONSUMER SPECIAL REPORT (FDA, Washington, DC), Jan. 1995, available at
http://www.fda.gov/fdac/special/newdrug/benefits.html (last visited Mar. 16, 2005). The
Kefauver-Harris Amendments were passed in 1962 in response to the Thalidomide incident,
in which a physician for the FDA successfully blocked approval of the sleeping pill for U.S.
sales, until it was discovered that the drug had caused deformities in Europe in children
whose mothers had taken thalidomide. DRUG LAW EVOLUTION, supra note 29. The
amendments established a mandatory reporting system for drug safety, and required drug
manufacturers to prove to the FDA the effectiveness of their product prior to marketing it.
Id.
32. CTR. FOR DRUG EVALUATION AND RESEARCH, FDA, DRUG APPROVAL APPLICATION
PROCESS, at http://www.fda.gov/cder/regulatory/applications/ (last visited Mar. 16, 2005).
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largest of FDA's five centers. 33 It has responsibility for both prescription
and over-the-counter drugs, whereas other centers have responsibility for
medical and radiological devices, food, cosmetics, biologics, and veterinary
drugs.34 The path to approval for pharmaceutical companies is not a short
and easy one, 35 but rather one that is characterized by substantial testing.
A company seeking to market a drug must submit evidence that it is
safe and effective by submitting a New Drug Application ("NDA"), which
is made after clinical tests are conducted.3 6 Even before clinical tests can
begin, researchers must first analyze the drug's main physical and chemical
properties in the laboratory, and study its pharmacologic and toxic effects
in laboratory animals. 37 If the laboratory and animal study results show
33. Id.
34. Id.
35. Recognizing the prolonged approval process, Congress modified regular patent law
specifically for drugs and pharmaceutical devices by providing for an extension of time to
compensate a patent holder for marketing time lost in satisfying the requirement that the
drug be not only useful under patent law, but safe and effective as well under the FDA
regulations. The Drug and Patent Term Restoration Act of 1984 modified regular patent
law specifically for drugs and pharmaceutical devices. Pub. L. No. 98-417, 98 Stat. 1585
(1984). First, it allows an extension for up to five years, not to exceed a fourteen year
period of exclusivity, to compensate a patent holder for marketing time lost in satisfying the
Food & Drug Administration requirement that the drug be not only useful (patent law) but
safe and effective as well. See generally 35 U.S.C. § 156 (2004). Second, it provides an
exemption (Bolar exemption) from claims of patent infringement for the acts of making,
using, or selling a patented invention which are "reasonably related to the development and
submission of information under a federal law which regulates the manufacture, use, or sale
of drugs." 35 U.S.C. § 271(e)(1) (2004). In other words, in seeking FDA approval to
market a drug, drug manufacturers are exempt from claims of infringements for using
patents to develop drugs, provided that no commercial use occurs before the patent expires.
Id. Third, there are special procedures for challenging the validity or infringement of drug
patents, which guarantee the patent owner a thirty-month preliminary injunction period
unless the dispute is adjudicated sooner. 21 U.S.C. § 355(c) (2004); 35 U.S.C. § 271(e)(2)(4) (2004). Finally, there is a 180 day period of market exclusivity for the first generic
applicant to file a challenge to patent validity, infringement, or enforceability for any
approved drug. 21 U.S.C. § 3550)(5)(B)(iv) (2004).
36. The CDER does not test drugs, although it's Office of Testing and Research does
conduct limited research in the areas of drug quality, safety, and effectiveness. TAMAR
NORDENBERG, INSIDE FDA: THE CENTER FOR DRUG EVALUATION AND RESEARCH, FDA
CONSUMER
(FDA,
Washington,
DC),
July-August
1996,
available at
http://www.fda.gov/fdac/features/696_cder.html (last visited Mar. 16, 2005).
37. CTR. FOR DRUG EVALUATION AND RESEARCH, FDA, DRUG APPLICATIONS:
INVESTIGATIONAL
NEW
DRUG
(IND)
APPLICATION
PROCESS,
at
http://www.fda.gov/cder/regulatory/applications/ind-page 1l.htm (last visited Mar. 16,
2005).
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promise, then the sponsor applies for an Investigational New Drug ("IND")
application to begin testing on people. 38 It is the cumulative results of these
tests that are detailed in the NDA and reviewed by CDER.39
Once the FDA has seen the sponsor's plans and a review board
approves the protocol for clinical trials, investigators may give the drug to a
small number of healthy volunteers or patients for Phase I tests, which
assess the most common acute adverse effects, and examine the size of
doses that patients can take safety without a high incidence of side
effects. 40 If Phase I studies reveal no major problems, such as unacceptable
toxicity, then researchers may conduct a clinical study in which the IND is
given to patients who have the condition it is intended to treat, in an effort
to determine whether or not the drug has a favorable effect on that
condition (Phase II).41 Phase III is typically a more expansive study with

38. Id. Before clinical tests can begin, researchers must first analyze the drug's main
physical and chemical properties in the laboratory and study its pharmacologic and toxic
effects in laboratory animals. Id. If the laboratory and animal study results show promise,
then the sponsor applies for an Investigational New Drug (IND) application to begin testing
on people. Id. The IND describes the chemical structure of the drug, how it works in the
body, the results of preclinical testing including any toxic side effects, the location and
protocol for the clinical tests, and how the drug will be manufactured. Id. During this
period the FDA offers sponsors opportunities to discuss the critical studies and overall
plans, so that they know what is expected with respect to study design, conduct, and
analysis. Id.
39. The Prescription Drug User Fee Act of 1992 required drug companies to pay fees
when submitting an NDA to the agency. Pub. L. No. 102-571, 106 Stat. 4491 (1992). The
Act also provided funds to hire more reviewers, and as a result, reduced the median time for
the completion of an NDA review. Id. The fee system continues as updated by the
Prescription Drug User Fee Amendments of 2002, 21 U.S.C §§ 301-509 (2004). The order
in which applications are looked at is determined with the aid of a classification system that
gives priority to drugs with the greatest potential benefit. FDA, Drug Review Priorities,at
http://www.fda.gov/fdac/special/newdrug/benrev.html (last visited Mar. 16, 2005). Priority
drugs are those appearing to represent an advance over available therapy, whereas standard
drugs are those appearing to have therapeutic qualities similar to those of an already
marketed drug. Id..
40. CTR. FOR DRUG EVALUATION AND RESEARCH, FDA, CDER HANDBOOK 8 (1998),
available at http://www.fda.gov/cder/handbook/handbook.pdf
[hereinafter
CDER
HANDBOOK]. Initial clinical studies also clarify what happens to a drug in the human body,
such as whether or not it is metabolized, how much of it gets into the blood and various
organs, how long it stays in the body, and how the body gets rid of the drug and its effects.
Id. Under federal regulations, proposed Phase I studies are evaluated almost exclusively for
safety reasons. Id.
41. Id. In a controlled trial, patients in one group receive the investigational drug, while
those in a control group get either no treatment at all, a placebo, a drug known to be
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tests being conducted on a larger population, and is designed to prove
conclusively that the drug is effective and better than the standard available
42 Once all of the clinical trials have been conducted, the sponsor
treatment. 42
submits the NDA, documenting what happened during the clinical tests,
how the drug is constituted, the results of the animal studies, how the drug
acts in the body, how it is manufactured, processed, and packaged,
especially the quality controls, and samples of the drug and its proposed
labels.43
Next, the review teams of CDER medical officers, chemists,
pharmacologists, statisticians, and other scientists review the sponsor's
NDA containing the relevant data and proposed labeling.44 Basically, the
effective, or a different dose of the drug under study. KEN

FLIEGER, TESTING DRUGS IN
PEOPLE, FDA CONSUMER SPECIAL REPORT (FDA, Washington, DC), Jan. 1995, available at

http://www.fda.gov/fdac/special/newdrug/testing.html (last visited Mar. 16, 2005). These
controlled clinical trials are important, because they provide the basis for demonstrating
effectiveness. Id.
42. CDER HANDBOOK, supra note 40, at 8-9. The FDA gives drug sponsors greater
freedom during Phase I, providing the investigations do not expose participants to undue
risks. Id. In evaluating Phase II and III investigations, however, FDA reviewers also must
ensure that these studies are of sufficient scientific quality to yield data that can support
marketing approval. Id.
43. CDER HANDBOOK, supra note 40, at 7. Per recommendation from the International
Conference on Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH), the FDA has published an ICH-developed guideline
for the drug industry on creating appropriate clinical study reports for FDA review. FDA,
GUIDELINE FOR INDUSTRY: STRUCTURE AND CONTENT OF CLINICAL STUDY REPORTS 1 (1996),

available at http://www.fda.gov/cder/guidance/iche3.pdf
(originally published in
International Conference on Harmonisation; Guideline on Structure and Content of Clinical
Study Reports; Availability, 61 Fed. Reg. 37,320 (July 17, 1996)) [hereinafter ICH
GUIDELINE]. The guideline has sections in which the sponsor should describe the overall
study design and plan (Investigational Plan), the patients participating in the study, and an
evaluation of both the drug's efficacy and safety, along with suggestions for supporting
information appropriate for inclusion. Id. at 1-3.
44. CDER HANDBOOK, supra note 40, at 22-23. The medical/clinical reviewers
(medical officers) are almost exclusively physicians.
FDA, THE REVIEW TEAM, at
http://www.fda.gov/fdac/special/newdrug/benteam.html (last visited, Mar. 16, 2005).
Clinical reviewers take the lead role in the NDA review and are responsible for synthesizing
the results of the animal toxicology, human pharmacology, and clinical reviews to formulate
the overall basis for a recommended agency action on the application. Id. The chemistry
reviewers address issues related to drug identity, manufacturing control, and analysis. Id.
The reviewing chemist evaluates the manufacturing and processing procedures for a drug to
ensure that the compound is adequately reproducible and stable. Id. The pharmacologists
and toxicologists evaluate the results of animal testing, and attempt to relate animal drug
effects to potential effects in humans. Id. Statisticians evaluate the statistical relevance of
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evaluators are examining whether the results of well-controlled studies
provide substantial evidence of effectiveness, and whether or not the results
of the clinical tests show that the product is safe under the conditions of use
in the proposed labeling, in the sense that the benefits of the drug appear to
outweigh its risks. 45 Regulatory law provides that clinical investigators,
including a sponsor-investigator, can be disqualified to receive
investigational new drugs if the investigator submits to the FDA or to the
sponsor false information in any required report.46 Additionally, the FDA
may refuse to approve a NDA,4 7 or withdraw approval of an application,
if
either is found to contain an untrue statement of a material fact. 48
49
C. FDA REGULATION OF DIETARY SUPPLEMENTS

If supplements were classified as drugs, manufacturers would be
subject to this process, and required to obtain FDA approval, complete with
scientific testing of product efficacy and safety, before marketing their
product to the public.50 Instead, supplements are a subcategory of food,
and regulated by the Dietary Supplement Health and Education Act of 1994
the data, including the methods used to conduct studies and to analyze the data, to give the
medical officers a better idea of the power of the findings to be extrapolated to the larger
patient population in the country. Id.
45. CDER HANDBOOK, supra note 40. The ICH guideline suggests that in the section
of the NDA concerning the safety evaluation of the drug data is to be analyzed at three
levels: 1) the extent of exposure (dose, duration, number of patients), 2) the more common
adverse events and laboratory test changes, and 3) serious adverse events and other
significant adverse events. ICH GUIDELINE, supra note 43, at 25. The report should
describe in a brief narrative these adverse events, supported by more detailed summary
tables of tabulations and data analyses, which include both the test drug and control
treatment groups so that a comparison can be made between them, and the events evaluated
in context. Id.
46. 21 C.F.R. § 312.70 (2004). If a danger to the public health exists as a result, the
FDA can terminate the IND immediately, and notify the sponsor of the determination, who
then may have an opportunity for a regulatory hearing. Id.
47. 21 C.F.R. § 314.125(a)(7) (2004).
48. 21 C.F.R. § 314.150(a)(2)(iv) (2004).
49. States have also attempted to regulate dietary supplements in intrastate commerce.
However, such controls implicate federal preemption issues. For a discussion of such
issues, see Stephanie Kauflin, Comment, Dietary Supplements. Is Availability Worth the
Risks? ProposedAlternatives to the Present DSHEA Scheme, 33 SETON HALL L. REV. 411,
429-435 (2003). Clearly state regulation of truth-in-advertising is more pervasive than state
regulation of the marketing of drugs. See infra notes 92-101 and accompanying text.
50. Peter A. Vignuolo, Note, The Herbal Street Drug Crisis: An Examination of The
Dietary Supplement Health and Education Act of 1994, 21 SETON HALL LEGIS. J. 200, 208

(1997).
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("DSHEA").51 A significant step in the direction of deregulation spurred
by consumer demands for ready access to dietary supplements, 52 this Act
changed the role of the FDA in the regulation of such products by
prohibiting their classification as
food additives or drugs, which would
53
necessitate pre-market approval.
Equally significant is the statutory presumption under DSHEA that
supplements are safe, which shifts the burden to prove otherwise to the
government.54 FDA regulatory authority is not triggered unless the
supplement poses a significant or unreasonable risk of illness or injury
under either conditions of use recommended in labeling, or in the absence
of such suggestions, under ordinary conditions of use. 55 As a result, a
dietary supplement such as Cellasene, a product touted as being an anticellulite agent, is presumed safe and unabashedly marketed as being
effective by its manufacturer without the need to supply proof of such
claims, as long as the claims concern the structure or function of the
51. Pub. L. No. 103-417, 108 Stat. 4325 (1994). The Act defines a dietary supplement
as a product (other than tobacco) that is intended to supplement the diet that bears or
contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or
other botanical, an amino acid, a dietary substance to supplement the diet by increasing the
total daily intake, or a concentrate, metabolite, constituent, extract, or combinations of these
ingredients, which is intended for ingestion in pill, capsule, tablet, or liquid form, not
represented for use as a conventional food or as the sole item of a meal or diet, and is
labeled as a "dietary supplement." 21 U.S.C § 321 (2004). For a discussion of the
legislation, see Overview of Dietary Supplements, supra note 5.
52. Tom Valuck, Note, Keeping Dietary Supplement Regulations Slim and Fit: Finding
a Balance Between Paternalism and Consumer Choice, 2 GEO. L.J. & PUB. POL'Y 285, 286
(2004).
53. Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary
Supplements: Examining Government Regulation Five Years After Enactmentof the Dietary
Health and Education Act of 1994, 54 FOOD & DRUG L.J. 567, 567-68 (1999). These
products are regulated instead as foods, which do not require FDA approval prior to
marketing. Id. at 568-69.
54. For a discussion of these changes and others made by the legislation, see Bruce H.
Schindler, Note, Where There's Smoke There's Fire: The Dangers of the Unregulated
Dietary Supplement Industry, 42 N.Y.L. SCH. L. REV. 261 (1998); Jeffrey A. Crossman,
Comment, "Sparing Cain: Executive Clemency In CapitalCases: " Mark McGwire Does It,
So Why Can't I? High School Use of Dietary Supplements and the Failureof DESHEA, 28
CAP. U.L. REV. 617, 617 (2000); Kelly Ann Kaczka, Comment, From Herbal Prozac to
Mark McGwire "s Tonic: How the Dietary Supplement Health and Education Act Changed
the Regulatory Landscapefor Health Products, 16 J. CONTEMP. HEALTH L. & POL'Y 463
(2000).
55. 21 U.S.C. § 342(f) (2004). The FDA also may regulate a dietary supplement if it
contains a new dietary ingredient. Id. at § 350b.
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product. 56 That is, DSHEA permits sellers to make statements about the
ability of dietary supplements to affect the structure or function of the body
(e.g., promote weight loss), provided there is a disclosure that 1) the FDA
has not evaluated the veracity of the claim, and 2) the product is not
intended to affect disease in a positive manner.57 The FDA does have the
authority to exercise greater pre-marketing regulatory authority for new
ingredients, however.58 In the case of new ingredients, there must be an
evidentiary basis that supports a reasonable expectation of safety for the
marketed use, and the FDA must be given information to support this
expectation within seventy-five days prior to marketing the supplement.59
In practice, the FDA, through its Center for Food Safety and Applied
Nutrition, must rely heavily on consumers, health professionals, and FDAregulated companies to report any problems experienced by someone using
a dietary supplement.6 ° Once a report is filed, the agency evaluates the
seriousness of the problem, and requests additional information from the
filer if necessary.6 1 In essence, the public must first buy a product and use
it long enough to develop health problems; in other words, the product

56. See Leticia M. Diaz, Cellasene or Endermologie, The Administrative Battle Against
Cellulite: Does FDA Approval Impress Consumers?, 20 QUINNIPIAC L. REV. 169 (2000), for

a discussion on the legal and public policy implications of a non-FDA approved anticellulite agent in comparison to one that is FDA approved.
57. 21 U.S.C. § 343(r)(6) (2004). See Margaret Gilhooley, Deregulation and the
Administrative Role: Looking at Dietary Supplements, 62 MONT. L. REV. 85, 95-110 (2001),

for a discussion on the scope of claims that can be made with respect to dietary
supplements, including structure and function claims.
58. New ingredients are defined as those not marketed in the United States prior to
October 15, 2004. 21 U.S.C. § 350b(c) (2004). Unfortunately, there is no apparent system
for monitoring whether or not new ingredients are being introduced without the proper
notification.
10 Years After the Implementation of DSHEA: the Status of Dietary
Supplements in the United States: Hearing Before the Subcomm. on Human Rights and
Wellness of the House Comm. on Government Reform, 108th Cong. 102 (March 24, 2004)

(statement of Dr. Annette Dickinson, President, Council for Responsible Nutrition).
59. The procedures are specified at 21 C.F.R. § 190.6 (2004). To date, the FDA has
objected to 68 pre-market notifications. For a discussion of these cases and an overview of
the process, see Michael McGuffin & Anthony L. Young, Premarket Notifications of New
DietaryIngredients A Ten- Year Review, 59 FOOD & DRUG L. J. 229 (2004).
60. The FDA website provides directions for reporting an adverse experience with a
dietary supplement. See Ctr. for Food Safety and Applied Nutrition, FDA, Dietary
Supplements

Adverse Event Reporting, at http://www.cfsan.fda.gov/-dms/ds-rept.html

(last visited Mar. 16, 2005).

61. FDA,

How TO REPORT PROBLEMS WITH PRODUCTS REGULATED BY

FDA, at

http://www.fda.gov/opacom/backgrounders/problem.html (last visited Mar. 16, 2005).
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must first hurt someone before the FDA will examine it. Clearly, the tragic
results produced by herbal fen-phen supplements in some cases illustrate
the deficiencies in the current regulatory system. 62 Furthermore, proving
that a product is dangerous can be difficult, since Section 401 of the FDCA
specifies that "a reasonable standard of quality" is all that is required for
companies to manufacture, distribute, and sell food.63
On the other hand, beyond producing and distributing safe products,
supplement manufacturers must comply with FDA specification regarding
accurate labeling. Dietary supplements must be labeled as such, and carry
a "Supplement Facts" panel that includes information such as the
appropriate serving size and a listing of nutrients, the percent of the daily
value of all dietary ingredients, and if it contains botanicals, it must identify
the part of the plant from which the ingredient was derived.64 If the FDA
concludes that a product has a false or misleading label, it will work with
the Federal Trade Commission (FTC), the agency primarily responsible for
truth
in advertising regulation for the protection of consumers to address
5
6

it.

62. See Jennifer Sardina, Note, Misconceptions and Misleading Information Prevail
Less Regulation Does Not Mean Less Danger to Consumers: Dangerous Herbal Weight

Loss Products, 14 J.L. & HEALTH 107, 117-23 (1999-2000), for a discussion on the deadly
and ineffective ingredients in herbal dietary supplements.
63. 21 U.S.C. § 341 (2004).
64. 21 C.F.R. § 101.36 (2004).
65. As a result of overlapping jurisdiction and shared inter-agency responsibilities, the
FDA has been seen as acting too slowly to protect the public from dangerous products, it
has even been sued, because of perceived slow response time. See Public Citizens Health
Research Group v. FDA, 740 F.2d 21 (D.C. Cir. 1984), where the Commissioner was sued
for delaying the imposition of mandatory warning labels on aspirin bottles, despite the
considerable scientific evidence that children with influenza or chicken pox who take aspirin
face a greatly increased risk of developing the often-fatal Reye's Syndrome. Id. However,
because an FDA investigation can dramatically affect sales, the agency should move
cautiously to fully validate the information before releasing any warnings to the public. The
FDA may even withhold information under the Freedom of Information Act, 5 U.S.C. § 552
(2004), while it investigates complaints, since records or information compiled for law
enforcement purposes are exempt under the Act. 21 C.F.R. § 20.64 (2004).

1136:33PM
4162005
4/16/2005 11:36:33 PM

BUJRKE
NX .DOC
BURK FINAL.DOC

Spring 2005]

REGULATING DIETARY SUPPLEMENTS

131

III. ADVERTISING REGULATION

Many of the claims asserted by sellers of dietary supplements contain
extraordinary claims of effectiveness, such as "discover the secret to
permanent weight loss," and "get weight off and keep it off.",66 In addition
to claims of effectiveness, safety attributes are flaunted as well. For
example, almost half of the ads analyzed in one study made safety-related
claims, such as "proven 100 percent safe," "safe, immediate weight loss,"
and "safest weight management system in the world." 67 If the product
itself is not subject to pre-market proof of safety and effectiveness, is the
regulation of truthfulness in advertising sufficient to deter marketing
supplements based on deceptive advertising claims?
A. THE FEDERAL TRADE COMMISSION
The Federal Trade Commission Act (FTCA) was passed by Congress
in 1914,68 which established the Federal Trade Commission. 69 The FTC's
mandate was to prevent entities from using unfair methods of competition
in commerce, 70 as well as to protect "not just the sophisticated, but rather
that 'vast multitude which includes ignorant, unthinking, and credulous,
who, in making purchases, do not stop to analyze, but are governed by
appearances and general impressions.' 71 Consequently, under Section 5 of
the FTCA, the FTC is empowered and directed to regulate deceptive acts or
practices in, or affecting, commerce, 72 which are defined as material

66. These claims appeared in twenty-three percent of the ads surveyed. BUREAU OF
CONSUMER PROTECTION, FTC, TIPPING THE SCALES? WEIGHT-LOSS ADS FOUND HEAVY ON

DECEPTION, at http://www.ftc.gov/bcp/conline/features/wgtloss.htm (last modified Sept.
2002) [hereinafter TIPPING THE SCALES].
67. Id.
68. Federal Trade Commission Act, Ch. 311, 38 Stat. 717 (1914) (codified as amended
at 15 U.S.C.S § 58 (1996)).
69. 15 U.S.C. § 41 (2004). "The FTC's duties are neither political nor executive, but
predominantly quasi-judicial and quasi-legislative." Humphrey's Ex'r v. United States, 295
U.S. 602, 624 (1935).
70. FTC v. Klenser, 274 U.S. 145, 151 (1927). In other words, part of the agency's
mission is to regulate unfair competition among businesses.
71. Floresheim v. Weinburger, 346 F. Supp 950, 957 (D.D.C. 1972) (citing Florence
Mfg. Co. v. J.C. Dowd & Co., 178 F. 73, 75 (2d Cir. 1910)).

72.

15 U.S.C. § 45(a)(1) (2004).
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representations, omissions, or practices that73are likely to mislead consumers
acting reasonably under the circumstances.
Deeming an act deceptive does not require a finding of fraud or an
intention to deceive.74 In determining how deceptive a product claim may
be, however, the FTC does make a distinction between actual deception
and sales puffing, which refers generally to "expressions of opinion not
made as representation of fact, and while the seller has some latitude in
puffing his goods, he is not authorized to misrepresent them or assign to
them benefits or virtues they do not possess. "175
Additionally, the FTC monitors unfair practices. 76 Unfair practices are
defined as those that cause or are likely to cause "substantial injury to
consumers which [are] not reasonably avoidable by consumers themselves
and not outweighed by countervailing benefits to consumers or to
competition., 77 The evaluation of unfairness considers such factors as
whether or not the practice offends public policy, is immoral, unethically
oppressive or unscrupulous, and causes substantial injury.78

73. In re Cliffdale Assocs., Inc., 46 Antitrust & Trade Reg. Rep. (BNA) 703 (1984).
See also FTC v. World Travel Vacation Brokers, Inc., 861 F.2d 1020 (7th Cir. 1988)
(defining deception as a practice, representation or omission that would likely mislead
consumers acting reasonably to their detriment). Previously, the standard for deception was
more lenient, focusing instead upon whether or not an advertisement had the capacity or
tendency to mislead consumers. See Charles of the Ritz Distrib. Corp. v. FTC, 143 F.2d 676
(2d Cir. 1944); Jack E. Karns & Alan C. Roline, The Federal Trade Commission's
Deception Policy in the Next Millennium: Evaluating the Subjective Impact of Cliffdale
Associates, 74 N.D. L. REV. 441 (1998) (discussing the new standard).
74. An intention to deceive, however, may affect the severity of the violation. Chrysler
Corp. v. FTC, 561 F.2d 357 (D.C. Cir. 1977). For an overview of the regulatory standard,
see note, Developments in the Law: Deceptive Advertising, 80 HARV. L. REV. 1005 (1967).
75. GulfOil Corp. v. FTC, 150 F.2d 106, 109 (5th Cir. 1945).
76. The Wheeler-Lea Amendment to the FTCA passed in 1938 clarified the roles of the
FDA and FTC in the regulation of advertising. See generally FTC v. Sperry Hutchinson
Co., 405 U.S. 233, 244 (1972). It also assured that the unfair practices prohibition was
intended to protect consumers, and not just claims of unfair competition between businesses.
Id. at 244.
77. 15 U.S.C. § 45(n) (2004).
78. In re Pfizer, Inc., 81 F.T.C. 23, 61 (1972). See also Southwest Sunsites, Inc., v.
FTC, 785 F.2d 1431 (9th Cir.), cert. denied, 479 U.S. 828 (1986); FTC v. Sperry &
Hutchinson Co., 405 U.S. 233, 240 (1972) (embracing the definition).
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The process by which the FTC seeks to stop unfair or deceptive
practices can be long and arduous.7 9 It must first issue and serve a
complaint stating its charges to the violator. 80 Only after a hearing in
which the party is proven guilty of violations may the FTC order a stop to
the unfair or deceptive trade practices. 81 However, if the offender files a
review within sixty days of the judgment, he may delay the process. 82 The
FTC's efforts to enjoin unfair practices may be further delayed in the event
of an appeal to the Supreme Court, in which case the company may
continue its practices until thirty days after the Supreme Court's ruling
even if the FTC ultimately prevails. 8 3 Such tactics can mean that a
deceptive practice might go on for years. Only after a cease and desist
order is finalized, can the FTC
impose monetary penalties of not more than
84
$10,000 for each violation.
Potential health hazards, as well as a deficiency in knowledge by the
public about medicinal qualities of products, have historically precipitated
a finding of deception in claims made by manufacturers of health-related
products. 85 The FTC has prosecuted and settled a number of cases
specifically dealing with the false advertising claims of dietary
supplements. For example, the Agency recently settled a case against the
marketers of "Focus Factor," a dietary supplement that claimed to improve
concentration, and "V-Factor," a supplement that claimed to enhance
sexual performance, for making untrue statements about scientific research

79. Generally the Commission issues a complaint when there is reason to believe that a
violation has occurred. A company can settle the complaint without admitting liability by
entering into a consent decree; alternatively, the FTC can hold an administrative
adjudication. OFFICE OF THE GEN. COUNSEL, FTC, A BRIEF OVERVIEW OF THE FEDERAL
TRADE

COMMISSION'S

INVESTIGATIVE

AND

LAW

ENFORCEMENT

AUTHORITY,

at

http://www.ftc.gov/ogc/brfovrvw.htm (last modified Sept. 2002).
80. 15 U.S.C. § 45(b) (2004).
81. Id.
82. 15 U.S.C. § 45(g)(1).
83. 15 U.S.C. § 45(g)(4).

84. 15 U.S.C. § 45(m).
85. See, e.g., Keele Hair & Scalp Specialists, Inc. v. FTC, 275 F.2d 18 (5th Cir. 1960)
(male-pattern baldness treatment); J.B. Williams Co. v. FTC, 381 F.2d 884 (6th Cir. 1967)
(iron supplement); Simeon Mgt. Corp. v. FTC, 579, F.2d 1137 (9th Cir. 1978) (weight

control product); Sterling Drug, Inc. v. FTC, 741 F.2d 1146 (9th Cir. 1984) (potential health
hazards associated with product's use).
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supporting their claims.8 6 The companies were ordered to pay substantial
sums ($1 million for "Focus Factor" and $60,000 for "V-Factor") in
consumer redress, yet neither company had to admit they were guilty of
deceptive advertising.8 7 Although the FTC prevailed after seven years of
legal battle, the companies were able to keep on running their ads, and
deceiving consumers during those years.
Misleading advertisements are especially prevalent for weight loss
products. In a 2001 review of three hundred current ads, the FTC found
that over half (55 percent) made at least one false or unsubstantiated
claim.88 Typical were promises such as "you can lose 18 pounds in one
week!"8 9 Others promised that there was no need for dietary restrictions or
exercise, that weight-loss would be permanent, and that the product was
safe. 90 Many of the advertisements included unsupported consumer
testimonials. 91 The FTC recently charged some marketers of CortiSlim and
CortiStress dietary supplements with making false and unsubstantiated
claims about the attributes of their products. By agreement, the parties
promised to cease making the claims that were the target of the complaint
brought by the FTC, and to limit future claims to those supported by
reliable scientific information.92
Some supplement advertisements go beyond simple deception and help
sustain dangerous products. "There are many worrisome, unfounded
claims. A lot of these products have not been proven to provide any benefit
and in some cases, may even present safety risks., 93 A much-publicized
case involving false claims for a dangerous product was the government's
action against Ephedrine Alkaloids. Classified as a dietary supplement,
ephedrine was widely marketed to help in weight-loss. In fact, it is
86. Press Release, FTC, MARKETERS OF THE SUPPLEMENTS "Focus FACTOR" AND "VFACTOR" AGREE TO SETTLE FTC CHARGERS AND PAY $1 MILLION (Mar. 17, 2004), at
http://www.ftc.gov/opa/2004/03/vitalbasics.htm (last visited Mar. 16, 2005).
87. Id.
88. TIPPING THE SCALES, supra note 66.
89. Id.
90. Id.
91. Id.
92. HEALTH SUPPLEMENT RETAILER, CORTISOL-CONTROL DIETARY SUPPLEMENTS DRAw
FTC ATTENTION, at http://www.hsrmagazine.com/hotnews/4ah5134638.html (last modified
Oct. 5, 2004).
93. BUREAU OF CONSUMER PROTECTION, FTC, PROMOTIONS FOR KIDS' DIETARY
SUPPLEMENTS

LEAVE

SOUR

TASTE,

http://www.FTC.gov/bcp/conline/features/kidsupp.htm (last modified May 2000).

at
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estimated that at least one percent of the U.S. adult population had taken a
supplement that contains ephedrine, thus putting them at risk for ischemic
and hemorrhagic
strokes,94 until the FDA banned its use for safety
95
concerns.
B.

STATE REGULATION UNDER DECEPTIVE TRADE PRACTICES
LEGISLATION

In addition to federal regulatory authority, all states have passed
Deceptive Trade Practices Acts ("DTPAs"). 96 Sometimes referred to as
"little FTC Acts," DTPAs prohibit deceptive acts or practices in the
conduct of trade or commerce along with a laundry list of deceptive trade
practices relating to unfair competition. 97 They were enacted in response to
the 1960's consumer empowerment movement, and are patterned after the
FTCA.98 Most of these statutes provide for enforcement either by the state

94. Weight Loss: Evidence Links Ephedra to Ischemic Stroke, HEALTH & MEDICINE
WEEK, 2004, at 884.
95. Press Release, FDA, FDA ISSUES REGULATION PROHIBITING SALE OF DIETARY
SUPPLEMENTS CONTAINING EPHEDRINE ALKALOIDS AND REITERATES ITS ADVICE THAT
CONSUMERS
STOP
USING
THESE
PRODUCTS
(Feb.
6,
2004),
at
http://www.cfsan.fda.gov/~lrd/fpephed6.html (last visited Mar. 16, 2005).
96. See Marshall A. Leaffer & Michael H. Lipson, Consumer Actions Against Unfair or
Deceptive Acts or Practices: The Private Uses of FTC Jurisdiction,48 GEO. WASH. L. REV.
521 (1982); William A. Lovett, State Deceptive Trade PracticeLegislation, 46 TULANE L.
REV. 724 (1971).
97. These practices include, false advertising, misleading product identification or
sponsorship, and disparagement. See Richard F. Dole, Jr., Merchant and Consumer
Protection: The Uniform Deceptive Trade Practices Act, 76 YALE L.J. 485 (1967), for a
discussion of the Act's provisions. Twelve states have passed either the 1964 or 1966
version of the Uniform Deceptive Trade Practices Act. See COLO. REV. STAT. § 6-1-105
(2000); DEL. CODE ANN. tit. 6, §§ 2532 to 2536 (2000); GA. CODE ANN. §§ 10-1-370 to 375 (2000); HAW. REV. STAT. ANN. §§ 481A-1 to -5 (2000); 815 ILL. COMP. STAT. ANN.
51011 to /7 (2001); ME. REV. STAT. ANN. tit. 10, §§ 1211 to 1216 (2000); MINN. STAT. §§
325D.43 to .48 (2000); NEB. REV. STAT. ANN. §§ 87-301 to -303.06 (2001); NEV. REV.
STAT. ANN. §§ 598.0905 to -0915 (2001); OHIO REV. CODE ANN. §§ 4165.01 to .04 (2000);
OKLA. STAT. tit. 78, §§ 51-55 (1999); OR. REV. STAT. § 646.608 (1999).
98. The standard under federal law for unfairness and for deception are usually
followed under state DTPAs, which focuses on whether or not a reasonable person would
likely be misled by the material representation or omission. See supra notes 73-78 and
accompanying text. See also William A. Lovett, Private Actions for Deceptive Trade
Practices,23 ADMIN. L. REV. 271 (1971) (discussing the history of the consumer movement
and early development of DTPAs).
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attorney general's office, or an administrative agency in charge of
consumer protection.99
Complementing the state's enforcement power are private causes of
action created by DTPAs for aggrieved consumers.100 But using such

99.
Under
(1993)
100.
permit

Debra D. Burke & Max Bishop, A Survey of the Potential Liability of Accountants
State Deceptive Trade Practices Acts, 23 U. MEM. L. REV. 805, 809-810 nn.17-18
(citing state statutory provisions).
Bringing suit under these acts is attractive to plaintiffs, since some state DTPAs
the recovery of punitive damages depending on the circumstances. CAL. CIv. CODE

§ 1780 (2001); CONN. GEN. STAT. § 42-11Og (1999); GA. CODE ANN. § 10-1-373 (2000);
IDAHO CODE § 48-608 (2000); 815 ILL. COMP. STAT. ANN. 505/2 (2000); Ky. REV. STAT.
ANN. § 367.220 (1998); Mo. REV. STAT. § 407.025 (1999); OR. REV. STAT. § 646.638
(1999); R.I. GEN. LAWS § 6-13.1-5.2 (2000). See also VT. STAT. ANN. tit. 9, § 2461 (2000)

(punitive damage award not to exceed three times the value given). Others allow the
recovery of treble damages. ALASKA STAT. § 45.50.531 (2000); ALA. CODE § 8-19-20
(2000); DEL. CODE ANN. tit., 6, § 2533 (2000); LA. REV. STAT. ANN. § 51.1409 (2000);
MONT. CODE ANN. § 30-14-133 (2000); NEV. REV. STAT. § 598A.210 (2000); N.H. REV.
STAT. ANN. § 358-A:10 (2000); N.J. STAT. ANN. § 56:8-19 (2000); N.Y. GEN. Bus. LAW §
349 (Consol. 2000); N. C. GEN. STAT. § 75-16 (2000); N.D. CENT. CODE § 51-15-09 (2000);
PA. STAT. ANN. tit. 73, § 201-9.2 (2000); S.C. CODE ANN. § 39-5-140 (1999); TENN. CODE
ANN. § 47-18-109 (2000); TEX. Bus. & COM. CODE § 17.50 (2000); WASH. REV. CODE §

19.86.090 (2000); Wis. STAT. § 100.201 (1999). See also COLO REV. STAT. § 6-1-113
(2000) (greater of $500 or three times actual damages); HAW. REV. STAT. § 480-13 (2000)
(greater of $1000 or three times actual damages); N.M. STAT. ANN. § 57-12-10
(2000)(greater of $300 or three times actual damages); UTAH CODE Ann. § 13-5-14
(2000)(greater of $2000 or three times actual damages); VA. CODE ANN. § 46A-6-106
(2000) (greater of $1000 or three times actual damages). Some states allow both, depending
on the circumstances. See MASS. ANN. LAWS ch. 93A, § 11 (2000); OHIO REV. CODE ANN.
§ 1345.09 (2000). Attorney's fees may be recoverable under some DPTAs. See, e.g., ARK.
STAT. ANN. § 4-88-113 (1999); IND. CODE ANN. § 24-5-0.5-4 (Burns 200); KAN. STAT.
ANN. § 50-634 (1999); MD. COM. LAW CODE ANN. § 13-408 (2000); MICH. COMP. LAWS §

445.911 (2000); MINN. STAT. § 325D.45 (2000); MISS. CODE ANN. § 75-24-15 (2000); Mo.
REV. STAT. § 407.025 (1999); MONT. CODE ANN. § 30-14-133 (2000); N.Y. GEN. Bus. LAW
§ 349 (Consol. 2000); OHIo REV. CODE ANN. § 1345.09 (2000); VT. STAT. ANN. tit. 9, §
2461 (2000); W. VA. CODE § 46A-6-101 (2000). Costs are sometimes recoverable as well.

See, e.g., ALA. CODE § 8-19-10 (2000); ALASKA STAT. § 45.50.537 (2000); CAL. CIV. CODE
§ 1780 (2001); COLO. REV. STAT. § 6-1-113 (2000); CONN. GEN. STAT. § 42-110g (1999);
DEL. CODE ANN. tit. 6, § 2533 (2000); FLA. STAT. § 501.207 (2000); GA. CODE ANN. § 101-373 (2000); HAW. REV. STAT. § 480-13 (2000); 815 ILL. COMP. STAT. § 505/10A (2000);
KY. REV. STAT. § 367.220 (1998); LA. REV. STAT. ANN. § 51.1409 (2000); ME. REV. STAT.
tit. 5, § 213 (1999); MASS. ANN. LAWS ch. 93A, § 11 (2000); NEB. REV. STAT. ANN. § 591609 (2000); NEV. REV. STAT. § 598A.210 (2000); N.H. REV. STAT. ANN. § 358-a:10
(2000); N.J. STAT. § 56:8-19 (2000); N.M. STAT. ANN. § 57-12-10 (2000); N.C. GEN. STAT.
§ 75-16.1 (2000); N.D. CENT. CODE § 51-15-09 (2000); OKLA. STAT. ANN. tit. 78, § 54
(1999); OR. REV. STAT. § 646.628 (1999); PA. STAT. ANN. tit. 73, § 201-9.2 (2000); R.I.
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private litigation as a catalyst for change is likely to proceed in a piecemeal
manner and produce patchwork results, which is less desirable than
centralized regulatory approach. 0 1
Even permitting enforcement by state attorney generals, whose
authority is limited to their respective states, is not preferable to a federal
regulatory scheme because most supplements are marketed nationwide.
Therefore, the regulation of advertising and marketing claims is best
accomplished by the FTC. However, given the constitutional protection
afforded to commercial speech, can claims about the safety and efficacy of
dietary supplements be regulated?
IV. FIRST AMENDMENT ISSUES
A. COMMERCIAL SPEECH AND FTC REGULATION
While on the surface, efforts to control deception in the marketplace
seem valid, there is a broader constitutional consideration: can these efforts
to protect the masses from spending their money, and endangering their
health override the protection of free speech? Although the First
Amendment guarantees free speech, courts have declared that commercial
speech is not as protected as other forms.10 2 In fact, courts have stated that
transaction-based speech, because of its103
nature, does not enjoy as much
protection from governmental regulation.

GEN. LAWS § 6-13.1-5.2 (2000); S.C. CODE ANN. § 39-5-140 (1999); TENN. CODE ANN. §
47-18-109 (2000); TEX. Bus. & COM. CODE § 17.50 (2000); UTAH CODE ANN. § 13-11-17.5
(2000); VA. CODE ANN. § 59.1-204 (2000); WASH. REV. CODE § 19.86.090 (2000); Wis.
STAT. § 100.201 (1999); WYO. STAT. ANN. § 40-12-113 (2000).

101. In addition to the FTC and state attorney generals, the National Advertising
Division of the Better Business Bureau may assist in the policing of false claims; however,
the continued growth of low quality products suggests these efforts are probably
insufficient. Pinco & Halpern, supra note 53, at 568. Additionally, supplement sellers are
subject to product liability law, which could make them responsible for injuries caused by
their products. A discussion of such liability under tort law and the Uniform Commercial
Code, however, is beyond the scope of this article. For an overview of the application of
such laws to dietary supplements see Robertson, supra note 1, at 328-340.
102. Va. State Bd. of Pharmacy v. Va. Citizens Consumer Council, Inc., 425 U.S. 748,
755 (1976).
103. Commercial speech is defined as "[that which does] no more than propose a
commercial transaction." Pittsburgh Press Co. v. Pittsburgh Comm'n on Human Relations,
413 U.S. 376, 385 (1973). See also Bogler v. Youngs Drug Products Corp., 463 U.S. 60
(1983) (holding that informational pamphlet on prophylactics contains commercial speech).
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In Virginia State Board of Pharmacy v. Virginia Citizens Consumer
Council Inc., 10 4 the Supreme Court recognized that "a different degree of
protection is necessary to insure that the flow of truthful and legitimate
commercial information is unimpaired."'10 5 Two years later, this finding
was repeated and clarified in Ohralik v. Ohio Bar Association.106 In

Ohralik, the Court ruled that not only does commercial speech deserve 10 a7
different level of protection, it deserves a lesser degree of protection.
Commercial speech is granted governmental protection only if it concerns a
lawful activity, and is not misleading; furthermore, under CentralHudson
Gas and Electric Corp. v. Public Service Commission of New York, 10 8 the
government interest in regulation must be substantial, the regulation must
directly advance the interest asserted, and be no more extensive than
necessary to further the governmental interest. 10 9 Therefore, the dietary
supplement industry's misleading
and deceitful speech should be afforded
10
no First Amendment protection.
Unfortunately, with volumes of new advertisements airing daily, some
even targeting children, FTC's old method of using official letters and

104. Va. State Bd. of Pharmacy, 425 U.S. at 748.
105. Id. at 772. See also Bates v. State Bar of Ariz., 433 U.S. 350 (1977) (restricting
speech could violate due process).
106. Ohralik v. Ohio Bar Assoc., 436 U.S. 447 (1978). Ohralik involved a ban on inperson solicitation, which the Court found to be constitutional. But see Zauderer v. Office
of Disciplinary Counsel of Supreme Court of Ohio, 471 U.S. 626 (1985) (upholding
constitutional right of attorneys to use printed advertisements seeking clients for class action
suits); Shapero v. Ky. Bar Assoc., 486 U.S. 466 (1988) (holding that direct mail solicitation
aimed at a specific audience constitutes protected speech).
107. Ohralik, 436 U.S. at 456.
108. Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm'n of N.Y., 447 U.S. 557
(1980).
109. Id. at 566. While the means asserted must be no more extensive than necessary to
further the governmental interest, the regulation need not be the least restrictive means of

protecting the governmental interest. Bd. of Trustees v. Fox, 492 U.S. 469 (1989). See
Todd J. Locher, Comment, Board of Trustees of the State University of New York v. Fox:
Cutting Back on CommercialSpeech Standards, 75 IOWA L. REV. 1335 (1990).
110. FTC v. Colgate-Palmolive Co., 380 U.S. 374 (1965). More recently, the Court has
found a state prohibition on alcohol-price advertising as being in violation of the First
Amendment. 44 Liquormart, Inc. v. Rhode Island, 517 U.S. 484 (1996). On the other hand,
it has upheld, against a facial challenge, a partial ban on the advertisement of certain forms
of casino gambling, where it is illegal for some members of the likely audience. Posadas de
P.R. Assoc. v. Tourism Co. of P.R., 478 U.S. 328 (1986). See Arlen W. Langvardt & Eric
L. Richards, The Death of Posadas and the Birth of Change in Commercial Speech
Doctrine: Implications of 44 Liquormart, 34 AM. Bus. L.J. 483 (1997).
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warnings to regulate product claims seem to be ineffective.1 1 On the other
hand, the government has a significant interest in regulating deceptive
advertisements that promise miracles to the public, and in requiring that a
company have a reasonable basis for believing that a claim is true before it
is made, particularly with respect to pharmaceutical products. 1 2 Can the
FTC go beyond the product manufacturer to regulate speech, and impose
fines on a company that broadcasts or prints a deceptive advertisement?
The FTC has prosecuted advertising agencies for developing
campaigns that they know, or should have known, to be false or
misleading.1 13 Yet holding a media company responsible for airing a false
advertisement is still considered taboo (not to mention implicating serious
First Amendment concerns), since it would require the broadcaster to
examine the products it agrees to advertise. 114 However, if the company
has a reason to believe that a commercial is deceptive, should it be required
to refuse to air the claim without proof of legitimacy? On occasion, the
courts have held the medium for a false advertisement responsible if it
knowingly or recklessly publishes a false claim.1 15 For example, a print
medium was held accountable when it acted maliciously and without
regard to the consequences that a reasonable person could have
1 17
anticipated,1 16 but not for a failure to investigate the truth of the claim.
111. SAMPLE WARNING LETTER FROM JOSEPH R. BACA, DIRECTOR, OFFICE OF
COMPLIANCE, CENTER FOR FOOD SAFETY AND APPLIED NUTRITION, FDA (Feb. 28, 2003), at
http://www.fda.gov/bbs/topics/NEWS/ephedra/warning.html (last visited Mar. 16, 2005).
112. See Thompson Med. Co., v. FTC, 791 F.2d 189 (D.C. Cir. 1986) (affirming FTC
decision requiring a company to provide the results of at least two well-controlled, doubleblinded studies before making efficacy claims for an over-the counter drug).
113. Doherty, Clifford, Steers & Shenfield, Inc. v. FTC., 392 F.2d 921, 927 (6th Cir.
1968) ("The advertising agency was an active participant in the preparation of the
advertisements and that the agency knew or had reason to know that [companyl's claims
were false or deceptive."). See also Gillette Co. v. Wilkinson Sword, Inc., 795 F. Supp. 662
(S.D.N.Y. 1992) for the proposition that in a non-FTC case, liability can attach unless the
advertising agency lacked actual knowledge of falsity, and had no reason to question
truthfulness.
114. Many states have statutes that exempt the media from false advertising claims as

long as they do not act recklessly, or with knowledge of falsity. See Jeffery S. Edelstein,
Self-Regulation of Advertising: An Alternative to Litigation and Government Action, 43
IDEA 509 (2003) for a list of these statutes, and an overview of media liability for false
advertising).

115. See, e.g., Goldstein v. Garlick, 318 N.Y.S.2d 370 (Sup. Ct. 1971).
116. Id. at 375.
117. Yuhas v. Mudge, 322 A.2d 824, 825 (N.J. Super. Ct. App. Div. 1974)
(advertisement for fireworks).
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Other media were found liable for carrying an advertisement that it should
have known was deceptive,118 and for the repetition of false
advertisements.1 19 Additionally, a publisher was held liable because it
carried an advertisement which, any reasonable
person could have
120
appreciated, would pose a substantial danger.
These cases are unusual, however, because there "have been few false
advertising lawsuits against the media, and fewer still have been
successful."1 21 To date, the FTC has not gone so far as to aggressively
regulate these media firms; instead it has held workshops and seminars in
the hope of inspiring self-regulation to control the flow of false and
misleading commercials.1 22 Most recently, a Commissioner from the FTC
implored the dietary supplement industry to regulate itself better, and called
for assistance from the media in weeding out "obvious fraud., 123 This
tactic may be effective with conscientious companies. For example, the
National Broadcasting Corporation monitors all advertising aired on its
124
networks for accuracy, reviewing over 50,000 commercials annually.
But not all firms airing dietary supplement claims are conscientious. Some
companies make millions through false advertising touting worthless or
even hazardous products. The simple truth is, it is extremely lucrative to
lie to consumers. Further, it should not be the responsibility of the media
to police dietary claims, particularly since that is not its area of expertise.

118. Thomas v. Times Mirror Mag., Inc., 159 Cal. Rptr. 711 (1979) (holding that a
publisher was liable for publishing classified advertisement for a licensed patent engineer
when the publisher was on notice that the engineer was excluded from practicing before the
Patent Office).
119. State v. Ginzburg, 428 N.Y.S.2d 132 (Sup. Ct. 1980) (enjoining a publisher with
proven fraudulent conduct from engaging in additional false advertising).
120. Braun v. Soldier of Fortune Mag., Inc., 968 F.2d 1110 (11 th Cir. 1992) (finding that
the advertisement could have reasonably been interpreted as an offer to commit a crime).
121. Edelstein, supra note 114, at 514. See Edelstein, supra note 114 for a discussion of
the ways in which the media exercises self-regulation of advertising claims.
122. See FTC, RED FLAG, BOGUS WEIGHT Loss CLAIMS: A REFERENCE GUIDE FOR MEDIA
ON
BOGUS
WEIGHT
Loss
CLAIM
DETECTION,
at
http://www.ftc.gov/bcp/conline/edcams/redflag/index.html (last visited Mar. 16, 2005).
123.

HEALTH SUPPLEMENT RETAILER, FTC COMMISSIONER CALLS ON INDUSTRY, MEDIA

TO WEED OUT FALSE CLAIMS, at http://www.hsrmagazine.com/hotnews/24h 18151855.html

(last updated Apr. 18, 2002).
124. Dateline NBC (NBC television broadcast, Nov. 16, 1997) (on file with author).
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A few cases raising free speech concerns have emerged even with
respect to the FDA's rather laissez-faire approach to the regulation of
dietary supplements. In Pearson v. Shalala,125 marketers of nutritional
supplements challenged the FDA's refusal to allow them to make a health
claim concerning the reduction in particular health risks (including cancer,
coronary disease, and neural tube defects) related to the consumption of
their products (e.g., antioxidant vitamins, fiber, omega-3 fatty acids and
folic acid). 126 The FDA standard for the approval of health claims on
dietary supplements was whether the claim was supported by "significant
scientific agreement., 127 The FDA had concluded that claims unsupported
by such proof were inherently misleading, because of their overwhelming
impact upon consumers. 128 While the appeals court acknowledged that the
government has a substantial interest under Central Hudson to prevent
consumer fraud, it questioned the fit between the goal and the means
chosen to advance it. 129 In sum, the court concluded that disclaimers on
labels concerning the degree of effectiveness could suffice to1 30reduce
consumer confusion while still respecting commercial speech rights
Subsequently, the FDA reconsidered the folic acid claim concerning
the reduction of neural tube defects, and still refused to authorize it, with or
without disclaimers. 31 As a result, the district court enjoined the FDA
from blocking the claim, concluding that the claim was only potentially
misleading, not inherently misleading, and as such, was protected by the
First Amendment. 132 In a later case, plaintiffs challenged the application of
the FDA guidance concerning "significant scientific agreement," which
125. Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999).
126. Id. at 652.
127. Id. at 653 (citing 21 C.F.R. § 101.14 (1998)).
128. Id.at 655-56.
129. Id.at 657.
130. Id.at 659.
131. Pearson v. Shalala, 130 F. Supp. 2d 105, 111 (D.D.C. 2001).
132. Id. at 120. The court found that there was scientific consensus that folic acid
substantially reduces the risk of giving birth to an infant with a neural tube defect. Id. As
such, the FDA's classification of the claim as being inherently misleading was an abuse of
discretion. Id. The court remanded the case with directions that the FDA draft "one or
more appropriately short, succinct, and accurate disclaimers." Id. See infra notes 145-152
and accompanying text for an overview of the FDA's response and interim system for
implementing a disclaimer-based approach.
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was issued subsequent to Pearson v. Shalala, and resulted in the FDA
blocking claims concerning the effect that anti-oxidant vitamins had upon
reducing the risk of certain cancers. In Whitaker v. Thompson,133 the
district court again determined that the claims were not inherently
misleading, and concluded that the FDA's prohibition on such advertising
violated the First Amendment because it was not
the least restrictive means
13 4
of protecting consumers from misinformation.
While some would argue that deference paid to the FDA in light of
First Amendment protection for commercial speech is eroding,1 35 both
Pearson and Whitaker involved health claims made by nutritional products,
not safety claims associated with other types of supplements, such as those
designed to control weight. Arguably, the governmental interest in
regulating nutritional value claims is weaker than for safety claims and any
substantiation requirements. 136 Concurring in the denial of a rehearing,
Judge Silberman of the D.C. Circuit, specifically reiterated that the decision
in Pearson recognized that the government did not assert 137that the
supplements at issue threatened the consumer's health and safety.
In other contexts the FDA has been able to control the spin associated
with marketing supplements. For example, the FDA successfully seized
products marketed as dietary supplements, which were intended to affect
the structure and function of the mind, as not falling within the statutory
definition of a supplement.1 38 Further, the Tenth Circuit upheld the FDA's
133. 248 F. Supp. 2d 1 (D.D.C. 2002).
134. Id. at 19. The court again remanded the case with directions that the FDA draft an
appropriate disclaimer. Id. at 20.
135. Edward M. Basile & Melanie Gross, The First Amendment and Federal Court
Deference to the Food and Drug Administration: The Times They Are-A-Changin ', 59 FOOD
DRUG L.J. 31 (2004).

136. Gilhooley, supra note 57, at 126-27.
137. Pearson v. Shalala, 172 F.3d 72 (D.C. Cir. 1999). In its petition for rehearing, the
FDA argued that since First Amendment concerns were not apparently implicated under the
previous system, whereby health claims transformed supplements into drugs (and subject to
regulatory pre-market approval), the "significant scientific agreement" standard should not
trigger such issues. Id. at 73. In other words, the FDA contended that it retained power to
allow only supplements to make health claims, which in its opinion met the significant
scientific agreement test, since previously it could have subjected all supplements that made
a health claims to the drug approval process. Id. Since the argument was raised on appeal
for the first time, the court declined to consider it at the rehearing stage. Id.
138. United States v. Undetermined Quantities of Articles of Drug, 145 F. Supp. 2d 692
(D. Md. 2001). The FDA classified the products as misbranded, unapproved alternatives to
street drugs. Id. at 696.
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interpretation that a dietary supplement excludes both active ingredients
and finished drug products, thus allowing the FDA to regulate supplements
with active ingredients as it does drugs. 139 Therefore, consistent with the
constitutional protection afforded commercial speech, should the FDA at
least do more with respect to safety claims made by the marketers of
dietary supplements?
V. REFORM PROPOSALS
When self-regulation has been tried and failed, the government needs
to aggressively pursue alternatives. A study conducted by the U.S.
Department of Health and Human Services concluded that FDA's
supervision of dietary supplements was inadequate. 140 Commentators have
also called for a reevaluation of FDA's role with respect to its regulation of
dietary supplements to ensure informed consumer choices. 14 1 Safe use
issues are critical, particularly since herbal supplements can be dangerous if
taken in combination with other medication.1 42 Even when taken alone,
some supplements can produce pharmacologic activity, such as changing
the heart rate or blood pressure in a user. 143 In addition, physicians have
called for reforms in areas ranging from the implementation of mandatory

139. Pharmaneux v. Shalala, 221 F.3d 1151 (10th Cir. 2000). The statutory definition
excludes articles approved as new drugs; therefore, if a supplement contains an active
ingredient, it must be approved through the FDA's drug approval process. See Kauflin,
supra note 49, at 425-29, for a discussion of the Undetermined Quantities of Articles of
Drug and Pharmaneuxcases.
140. See OFFICE OF THE INSPECTOR GEN., DEP'T OF HEALTH AND HUMAN SERVICES,
ADVERSE EVENT REPORTING FOR DIETARY SUPPLEMENTS: AN INADEQUATE SAFETY VALVE

(Apr. 2001), available athttp://oig.hhs.gov/oei/reports/oei-01-00-00180.pdf.
141. See Gilhooley, supra note 57, at 124-30 (arguing for a substantiation model for
safety claims). See also Sardina, supra note 62, at 123-32 (calling for legislative
amendments to DSHEA to regulate purity levels and increased FDA funding); Kauflin,
supra note 49, at 435-46 (reforms should include shifting the burden to the manufacturer to
prove safety, permitting the FDA to act against dietary supplements as a class rather than
individually, and requiring prescriptions for supplements, which can be dangerous in higher
dose than that suggested on the label); Valuck, supra note 52, at 311-13 (proposing
regulation based upon safety risk, use of third party reviewers, and increased efforts by all
affected parties to deter fraudulent marketing).
142. Kauflin, supra note 49, at 411. Adverse side effects may occur as well. Id. at 412.
143. Six Years After the Establishment of DSHEA: The Status of National and
International Dietary Supplement Research and Regulation: Hearing on Dietary
Supplements Before the House Comm. on Government Reform, 107th Cong. 89 (2001)
(testimony of Sidney M. Wolfe, M.D.).
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adverse event reporting requirements
for dietary supplement
manufacturers, and requirements for mandatory warnings for risks,
registration of companies and products, to the identification
of the raw
144
source.
their
with
along
products
the
in
contained
materials
To date, the FDA has undertaken several initiatives with respect to
improving the regulation of dietary supplements. First, the FDA, pursuant
to the mandate in DSHEA to develop regulations to ensure that
supplements are pure, promulgated a rule on good manufacturing practices
to prevent both super- and sub-potent products. 145 The proposed rule seeks
to establish Current Good Manufacturing Practices ("CGMPs") that include
provisions on manufacturing, packaging, labeling, testing, quality control,
releasing for distribution, and holding of dietary ingredients and dietary
supplements
all of which are intended to ensure that manufacturing,
packing, and holding practices
will not result in an adulterated or
146
misbranded dietary supplement.
Second, the FDA has proposed new processes for monitoring health
care claims in the wake of Pearson.147 In one guideline, the FDA illustrates
the process for evaluating and ranking health claims.1 48 Another guideline
details how applicants can seek a qualified health claim, and describes
FDA priorities for reviewing such claims. 149 Together, the guidelines

144. Id. at 90.
145. CTR. FOR

FOOD SAFETY AND APPLIED NUTRITION AND OFFICE OF NUTRITIONAL
PRODUCTS, LABELING AND DIETARY SUPPLEMENTS, FDA, FACT SHEET ON FDA's STRATEGY
FOR DIETARY SUPPLEMENTS, at http://www.cfsan.fda.gov/-dms/ds3strfs.html (last modified

Nov. 4, 2004). Commentators previously had called for the development of such practices,
along with their mandatory implementation. See, e.g., Robertson, supra note 1, at 343;
Sardina, supra note 62, at 128.
146. Current Good Manufacturing Practice in Manufacturing, Packing, or Holding
Dietary Ingredients and Dietary Supplements, 68 Fed. Reg. 12,158 (proposed Mar. 13,
2003). Due to the substantial number of comments, the rule has not yet been finalized,
pending further review of the feedback. In addition, CGMPs exist with respect to drugs.
See Current Good Manufacturing Practice for Finished Pharmaceuticals, 21 C.F.R. § 211
(2005).
147. See discussion on the Pearson cases, supra notes 125-34 and accompanying text.

148.

CTR. FOR FOOD SAFETY AND APPLIED NUTRITION,

FDA,

GUIDANCE FOR INDUSTRY

FDA: INTERIM EVIDENCE-BASED RANKING SYSTEM FOR SCIENTIFIC DATA, at
http://www.cfsan.fda.gov/-dms/hclmgui4.html (last modified July 10, 2003).
149. CTR. FOR FOOD SAFETY AND APPLIED NUTRITION, FDA, GUIDANCE FOR INDUSTRY
AND FDA: INTERIM PROCEDURES FOR QUALIFIED HEALTH CLAIMS IN THE LABELING OF
AND

CONVENTIONAL

HUMAN

FOOD

AND

HUMAN

DIETARY

SUPPLEMENTS,

http://www.cfsan.fda.gov/-dms/hclmgui3.html (last modified July 10, 2003).

at
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provide a grading system for health claims based upon an analysis of the
scientific data submitted and the level of comfort concerning the validity of
the claim, coupled with a correlative standard disclaimer. For example, the
qualifying language for evidence ranked with a B grade is: "although there
is scientific evidence supporting the claim, the evidence is not conclusive,"
while a grade of C has this language: "some scientific evidence suggests
...however, [the]
FDA has determined that this evidence is limited and
1 50
not conclusive.
Third, the FDA is preparing to issue another draft guidance concerning
substantiation for dietary supplement claims. The FTCA requires that a
manufacturer of a dietary supplement making a nutritional deficiency,
structure/function, or general well-being claim has substantiation that the
claim is truthful and not misleading. 151 This proposed guidance, which has
been distributed for comment purposes, recommends that the test for
compliance with the substantiation standard include an assessment of the
meaning of the claims being made, the relationship of the evidence
to the
152
claims, the quality of the evidence, and the totality of the evidence.
In addition to these three reforms, the FDA remains vigilant in its
enforcement actions and in seizing misbranded drugs. 153 Yet these
improvements and efforts fall short of the mark for a couple of reasons.
First, the guidelines issued by the FDA are just that: non-binding
recommendations, which permit alternative approaches, so long as the
statutes and regulations are satisfied. Second, there is an insufficient
barrier to pre-market approval of supplements, since the FDA's role is

150. Id. A grade of 'D' would indicate an extremely low level of comfort with the
evidentiary support of the claim, such that appropriate qualifying language should suggest
that: "very limited and preliminary scientific research suggests ...FDA concludes that there
is little scientific evidence supporting this claim." Id.
151. 21 U.S.C. § 343(r)(6) (2004).
152. For a further explanation of the proposal, see CTR. FOR FOOD SAFETY AND APPLIED
NUTRITION AND OFFICE OF NUTRITIONAL PRODUCTS, LABELING AND DIETARY SUPPLEMENTS,
FDA, FACT SHEET ON FDA'S DRAFT GUIDANCE FOR INDUSTRY: SUBSTANTIATION FOR
DIETARY SUPPLEMENT CLAIMS, at http://www.cfsan.fda.gov/-dms/dsclmfs.html
(last

modified Nov. 4, 2004).
153. 10 Years after the Implementation of DSHEA: The Status of Dietary Supplements in
the United States: Hearing Before the Subcomm. on Human Rights and Wellness of the
House Comm. on Government Reform, 108th Cong. 53-63 (2004) (statement of Dr. Robert
Brackett, Director, Center for Food Safety and Applied Nutrition).
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either limited to new ingredients
or is reactionary in light of a significant or
154
unreasonable risk of illness.
Safety substantiation, instead, should be regulated in a manner similar
to that employed for drugs. Manufacturers of dietary supplements should
155
be required to test their products through a Phase I type of procedure.
Should Phase I studies identify risks, the FDA should mandate that
appropriate warnings and dosages accompany the product. Because Phases
II and III primarily address effectiveness concerns, 156 Phase I studies
should be sufficient. Why? Consumers want ready access to supplements
because they, along with nutrition experts, 157 believe they are effective. As
long as they are safe, such ready access should be permissible. As for
protecting the economic interests of the consumers from the bogus claims
by supplement manufacturers, both the FTC 158 and state DTPAs 159 have the
proper authority to pursue these claims.
However, unlike economic losses, unsafe use or unsafe products
potentially may pose serious health risks, which are not likely to be
appreciated by an ordinary consumer. While the FDA does have a process
in place for the reporting of adverse events,1 60 that process would be more
controlled and less fortuitous if manufacturers were required to report and
monitor adverse events in controlled clinical studies, such as the Phase I
trials required for drugs. Additionally, similar to its regulatory authority
over drugs, the FDA should be empowered to require post-marketing
studies in appropriate cases. Under a section of the Food and Drug
154. See supra notes 50-65 and accompanying text.
155. See supra notes 36-40 and accompanying text.
156. See supra notes 41-43 and accompanying text. As such, they are designed to
address efficacy, and are more equivalent to permissible health claims.
157. See infra notes 165-68 and accompanying text.
158. See supra notes 68-95 and accompanying text, for a discussion on FTC's authority
to regulate false advertising. This authority, in conjunction with the health claims rating
system and suggested disclaimers should suffice.
159. See supra notes 96-101 and accompanying text.
160. See CTR. FOR FOOD SAFETY AND APPLIED NUTRITION, FDA, ADVERSE EVENT
REPORTING SYSTEM, at http://www.cfsan.fda.gov/-dms/ds-rept.html (last visited Mar. 16,

2005). The Center for Food Safety and Applied Nutrition has a computerized "Adverse
Event Reporting System," which records, through one portal, voluntary reports from
consumers, health care providers and the industry. Id. But query whether or not consumers
are capable of tracing the cause of an adverse health event to the use of a dietary
supplement. In other words, would consumers make the connection? Even if they did
properly access the alleged cause of their malady, how many would actually report the
incident to the FDA?
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Administration Modernization Act of 1997, the FDA has the authority to
monitor the progress of post-marketing studies that drug and biologics
applicants have agreed to conduct. 161 The FDA should be empowered to
promulgate a rule that addresses those cases in which post-marketing
studies should be required.
To this end, there are a few Congressional initiatives that bear
mentioning. The Dietary Supplement Information Act proposes to amend
the FTCA to require manufacturers of dietary supplements to register with
the FDA, and submit reports on adverse events to the FDA. 162 Likewise,
the Dietary Supplement Safety Act of 2003 would also require
manufacturers to submit reports on adverse events to the FDA. 163 Both
bills provide for a post-market surveillance plan in certain circumstances.
The Dietary Supplement Awareness Act provides for manufacturer
registration, post-market surveillance and closer scrutiny for supplements
that may pose a significant risk to minors.1 64 This type of initiative,
coupled with pre-market FDA approval concerning the safety of the
supplement, along with its recommended use and dosage instructions and
appropriate risk disclaimers, would go far in improving the system.
VI. CONCLUSION

Certainly, good nutrition is a national concern. Obesity is a serious
issue with substantial numbers of Americans being overweight, and
suffering health problems as a result.1 65 It is also clear that the average
American diet lacks certain essential nutrients, which dietary supplements
could provide. 166 Further, a nutritious diet complemented by dietary

161. 21 U.S.C. § 356b (2004). Applicants who are required by FDA, or who have
entered into an agreement with FDA, to conduct a post-marketing study are also required to
provide the Agency with an annual report on the status of the study until it is completed or
terminated. 21 U.S.C. § 356b(a) (2004).
162. H.R. 724, 108th Cong § 416(a)-(b) (2003).
163. H.R. 722, 108th Cong (2003).
164. H.R. 3377, 108th Cong (2003).
165. Government Role in Combating Obesity: Hearing Before the House Comm. on

Government Reform, 108th Cong. 1-2 (2004) (testimony of Lester M. Crawford, Acting
Commissioner of Food and Drugs, Department of Health and Human Services).
166. For example, calcium supplements can complement a diet that otherwise does not
meet the recommended amount of calcium, which is essential for reducing the natural
occurrence of bone loss. Dietary Supplements: Nature's Answer to Cost Effective
PreventativeMedicine: Hearing Before the Subcomm. on Human Rights and Wellness of the
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supplements can reduce the risk of certain diseases, and the related high
health care costs.' 67 Even physicians embrace dietary supplement therapies
as a part of the practice of integrative medicine.168 Yet more must be done
to insure the safety, if not the efficacy, of these products, in order to avert
the types of problems encountered in the marketing of such supplements as
ephedrine alkaloids (used for weight control and loss) and androstenedione
(used for anabolic effects and for enhancing athletic performance) 169 Even
Dr. Paul M. Coates, Director of the Office of Dietary Supplements for the
National Institutes of Health, recently acknowledged in testimony before a
Congressional committee that "of the approximately [30,000] dietary
supplements on the market there are many that have not undergone the
170
rigorous scientific testing needed to establish their efficacy and safety.,
While the FDA drug approval process is not perfect, as recent incidents
involving the drugs Vioxx and Celebrex have shown, it is certainly more
rigorous and reliable than the current regime for supplements, and should
be a model for FDA regulation of dietary supplements.

House Comm. on Government Reform, 108th Cong. 5 (2004) (testimony of Dr. Barbara
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